Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014, Article ID 828732, 7 pages
http://dx.doi.org/10.1155/2014/828732
Clinical Study

The Effect of Combination Therapy with Rituximab and Intravenous Immunoglobulin on the Progression of Chronic Antibody Mediated Rejection in Renal Transplant Recipients

1Division of Nephrology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
2Division of Nephrology, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Republic of Korea
3Dialysis Department, National Research Center for Maternal and Child Health, Astana, Kazakhstan
4Transplant Research Center, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
5Department of Hospital Pathology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

Received 15 June 2013; Revised 28 October 2013; Accepted 11 November 2013; Published 29 January 2014

Academic Editor: Qiquan Sun

Copyright © 2014 Gun Hee An et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Hirai, N. Kohei, K. Omoto, H. Ishida, and K. Tanabe, “Significance of low-level DSA detected by solid-phase assay in association with acute and chronic antibody-mediated rejection,” Transplant International, vol. 25, no. 9, pp. 925–934, 2012. View at Publisher · View at Google Scholar
  2. J. Pascual, M. J. Perez-Saez, M. Mir, and M. Crespo, “Chronic renal allograft injury: early detection, accurate diagnosis and management,” Transplantation Reviews, vol. 26, no. 4, pp. 280–290, 2012. View at Publisher · View at Google Scholar
  3. G. Einecke, B. Sis, J. Reeve et al., “Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure,” The American Journal of Transplantation, vol. 9, no. 11, pp. 2520–2531, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Solez, R. B. Colvin, L. C. Racusen et al., “Banff '05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (“CAN”),” The American Journal of Transplantation, vol. 7, no. 3, pp. 518–526, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. F. G. Cosio, J. M. Gloor, S. Sethi, and M. D. Stegall, “Transplant glomerulopathy,” The American Journal of Transplantation, vol. 8, no. 3, pp. 492–496, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Mauiyyedi, P. D. Pelle, S. Saidman et al., “Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries,” Journal of the American Society of Nephrology, vol. 12, no. 3, pp. 574–582, 2001. View at Google Scholar · View at Scopus
  7. P. I. Terasaki and M. Ozawa, “Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial,” Transplantation, vol. 80, no. 9, pp. 1194–1197, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Billing, S. Rieger, J. Ovens et al., “Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients,” Transplantation, vol. 86, no. 9, pp. 1214–1221, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Billing, S. Rieger, C. Susal et al., “IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up,” Transplant International, vol. 25, no. 11, pp. 1165–1173, 2012. View at Publisher · View at Google Scholar
  10. T. Fehr, B. Rüsi, A. Fischer, H. Hopfer, R. P. Wüthrich, and A. Gaspert, “Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection,” Transplantation, vol. 87, no. 12, pp. 1837–1841, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. A. Hong, H. G. Kim, S. R. Choi et al., “Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection,” Transplantation Proceedings, vol. 44, no. 1, pp. 182–184, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. A. S. Levey, J. Coresh, T. Greene et al., “Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate,” Annals of Internal Medicine, vol. 145, no. 4, pp. 247–254, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. S. C. Jordan, A. A. Vo, A. Peng, M. Toyoda, and D. Tyan, “Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients,” The American Journal of Transplantation, vol. 6, no. 3, pp. 459–466, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. A. D. Salama and C. D. Pusey, “Drug insight: rituximab in renal disease and transplantation,” Nature Clinical Practice Nephrology, vol. 2, no. 4, pp. 221–230, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. B. J. Nankivell, R. J. Borrows, C. L.-S. Fung, P. J. O'Connell, R. D. M. Allen, and J. R. Chapman, “The natural history of chronic allograft nephropathy,” The New England Journal of Medicine, vol. 349, no. 24, pp. 2326–2333, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. J. M. Halimi, M. Buchler, A. Al-Najjar et al., “Urinary albumin excretion and the risk of graft loss and death in proteinuric and non-proteinuric renal transplant recipients,” The American Journal of Transplantation, vol. 7, no. 3, pp. 618–625, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. J. M. Halimi, “Low-grade proteinuria and microalbuminuria in renal transplantation,” Transplantation, vol. 96, no. 2, pp. 121–130, 2013. View at Publisher · View at Google Scholar
  18. A. Djamali, M. Samaniego, J. Torrealba, J. Pirsch, and B. L. Muth, “Increase in proteinuria >200 mg/g after late rejection is associated with poor graft survival,” Nephrology Dialysis Transplantation, vol. 25, no. 4, pp. 1300–1306, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Kieran, X. Wang, J. Perkins et al., “Combination of peritubular C4d and transplant glomerulopathy predicts late renal allograft failure,” Journal of the American Society of Nephrology, vol. 20, no. 10, pp. 2260–2268, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Sis, P. M. Campbell, T. Mueller et al., “Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause,” The American Journal of Transplantation, vol. 7, no. 7, pp. 1743–1752, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Vongwiwatanaa, S. Gourishankara, P. M. Campbella, K. Solez, and P. F. Hallorana, “Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy,” The American Journal of Transplantation, vol. 4, no. 1, pp. 124–129, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. R. N. Smith, F. Malik, N. Goes et al., “Partial therapeutic response to rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts,” Transplant Immunology, vol. 27, no. 2-3, pp. 107–113, 2012. View at Publisher · View at Google Scholar
  23. C. A. Vieira, A. Agarwal, B. K. Book et al., “Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics,” Transplantation, vol. 77, no. 4, pp. 542–548, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. M. R. Clatworthy, “Targeting B cells and antibody in transplantation,” The American Journal of Transplantation, vol. 11, no. 7, pp. 1359–1367, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. M. J. Everly, “A summary of bortezomib use in transplantation across 29 centers,” Clinical Transplants, pp. 323–337, 2009. View at Google Scholar · View at Scopus
  26. M. J. Everly, “An update on antibody reduction and rejection reversal following bortezomib use: a report of 52 cases across 10 centers,” Clinical Transplants, pp. 353–362, 2010. View at Google Scholar · View at Scopus
  27. E. Schwaiger, H. Regele, M. Wahrmann et al., “Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report,” Clinical Transplants, pp. 391–396, 2010. View at Google Scholar · View at Scopus
  28. C. A. Siegrist and R. Aspinall, “B-cell responses to vaccination at the extremes of age,” Nature Reviews Immunology, vol. 9, no. 3, pp. 185–194, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. V. Zarkhin, P. A. Lovelace, L. Li, S. C. Hsieh, and M. M. Sarwal, “Phenotypic evaluation of B-cell subsets after rituximab for treatment of acute renal allograft rejection in pediatric recipients,” Transplantation, vol. 91, no. 9, pp. 1010–1018, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Solez, R. B. Colvin, L. C. Racusen et al., “Banff 07 classification of renal allograft pathology: updates and future directions,” The American Journal of Transplantation, vol. 8, no. 4, pp. 753–760, 2008. View at Publisher · View at Google Scholar · View at Scopus